Evidence map›Paper›PMID 27984128›Full record

ReviewToxicology and applied pharmacology2016

DNA damage response in nephrotoxic and ischemic kidney injury.

Mingjuan Yan, Chengyuan Tang, Zhengwei Ma, Shuang Huang, Zheng Dong

Abstract readReview
In one paragraph

Review in Toxicology and applied pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Cellular senescence in kidney diseases.Chinese medical journal · 2025
    Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mingjuan YanDepartment of Nephrology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, PR China.
Chengyuan TangDepartment of Nephrology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, PR China.
Zhengwei MaDepartment of Cellular Biology & Anatomy, Medical College of Georgia at Augusta University and Charlie Norwood VA Medical Center, Augusta, GA 30912, USA.
Shuang HuangDepartment of Anatomy and Cell Biology, University of Florida College of Medicine, Gainesville, FL, USA.
Zheng DongDepartment of Nephrology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, PR China; Department of Cellular Biology & Anatomy, Medical College of Georgia at Augusta University and Charlie Norwood VA Medical Center, Augusta, GA 30912, USA. Electronic address: zdong@augusta.edu.

Funding

DNA methylation in kidney repair after ischemic AKIR01DK058831 · NIDDK · UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT · PI DONG, ZHENG · 2001 to 2025
$7.5M
Kidney Injury by Cisplatin and Renoprotective Strategies.R01DK087843 · NIDDK · AUGUSTA UNIVERSITY · PI DONG, ZHENG · 2010 to 2025
$5.8M
Molecular Regulation of Ischemic Renal FailureI01BX000319 · VA · CHARLIE NORWOOD VA MEDICAL CENTER · PI Zheng Dong · 2009 to 2026
–
BLRD VA I01 BX000319NIDDK NIH HHS R01 DK058831NIDDK NIH HHS R01 DK087843
6 · The paper itself

Abstract

DNA damage activates specific cell signaling cascades for DNA repair, cell cycle arrest, senescence, and/or cell death. Recent studies have demonstrated DNA damage response (DDR) in experimental models of acute kidney injury (AKI). In cisplatin-induced AKI or nephrotoxicity, the DDR pathway of ATR/Chk2/p53 is activated and contributes to renal tubular cell apoptosis. In ischemic AKI, DDR seems more complex and involves at least the ataxia telangiectasia mutated (ATM), a member of the phosphatidylinositol 3-kinase-related kinase (PIKK) family, and p53; however, while ATM may promote DNA repair, p53 may trigger cell death. Targeting DDR for kidney protection in AKI therefore relies on a thorough elucidation of the DDR pathways in various forms of AKI.

Indexed as

DNA DamageAcute Kidney InjuryCisplatinHumansIschemiaKidneyReperfusion InjuryCisplatinAcute kidney injuryCisplatinDNA damage responseRenal ischemia/reperfusion

Identifiers

PMID27984128
PMCPMC5362306

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.